Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF: Ruxolitinib vs Hydroxyurea in Polycythemia Vera Symptoms
NCT01632904Phase 3Completed
- Sponsor
- Incyte
- Start
- Jun 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of ruxolitinib in polycythemia vera (PV) (2 arms), sponsored by Incyte. Primary endpoint: Total Symptom Score-Cytokine Response at 16 weeks. Started Jun 2012; status: completed.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT01632904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01632904.